Discovering Tomorrow’s Medicines Today^™

PhD student Sophie Venet (right) closely examines the telltale tracks of a culture sample in a petri dish. Welcome to NovImmune!

NovImmune In Person — Join us at the Immunomodulatory Therapeutic Antibodies for Cancer 2013 conference in Boston, August 13–15, at the International Bioanalytical Congress in Berlin, September 11–12, at the BioProduction 2013 conference in Dublin, October 22–23, and at PEGS Europe in Lisbon, November 4–8, for a wide variety of presentations. See Coming Events for speakers, details, and links.

NEWS: NovImmune initiates Phase I clinical study with first-in-class anti-TLR4 monoclonal antibody — NovImmune initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4).